Ocular Therapeutix OCUL Business Segments — Interest Expense Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ocular Therapeutix's business segments — interest expense nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ocular Therapeutix's business segments — interest expense nonoperating?
- Ocular Therapeutix (OCUL) reported business segments — interest expense nonoperating of $2.78M in Q1 2026.
- How has Ocular Therapeutix's business segments — interest expense nonoperating changed year-over-year?
- Ocular Therapeutix's business segments — interest expense nonoperating decreased by 6.9% year-over-year, from $2.98M to $2.78M.
- What is the long-term trend for Ocular Therapeutix's business segments — interest expense nonoperating?
- Over 3 years (2022 to 2025), Ocular Therapeutix's business segments — interest expense nonoperating has grown at a 145.7% compound annual growth rate (CAGR), from -$798K to $11.83M.
- What does business segments — interest expense nonoperating mean?
- This metric captures the costs incurred on debt obligations and other financing arrangements that are not directly tied to core operational activities. It reflects the company's cost of capital and its reliance on external debt financing to fund research and development or commercialization efforts. High levels of interest expense can indicate significant financial leverage and potential liquidity risk.